RxSight, Inc.
For the period ended Apr 21, 2025. Filed Apr 21, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Apr 21, 2025 · Filed Apr 21, 2025
Contents
PAY VERSUS PERFORMANCE
The following table sets forth the compensation for Ron Kurtz, M.D., our principal executive officer (“PEO”), and the average compensation for our named executive officers other than our PEO (“non-PEO NEOs”) for fiscal years 2024, 2023, and 2022 (each a “Covered Year”), both as reported in the Summary Compensation Table and with certain adjustments to reflect the “compensation actually paid” to such individuals, as calculated in accordance with rules adopted by the SEC in August 2022. “Compensation actually paid” does not reflect amounts actually realized by our PEO and Non-PEO NEOs and may be higher or lower than amounts, if any, that are actually realized by such individuals. The table below also provides information for each Covered Year regarding our cumulative total shareholder return, the total shareholder return of the S&P Healthcare & Supplies Index, our net income, and our revenue.
| Value of Initial Fixed $100Investment Based on: | ||||||||
|---|---|---|---|---|---|---|---|---|
| Year | Summary CompensationTable Total for PEO ($)(1) | Compensation ActuallyPaid to PEO ($)(1)(2)(3) | Average Summary Compensation Table Total for Non-PEO NEOs ($)(1) | Average Compensation Actually Paid to Non-PEO NEOs ($)(1)(2)(3) | Total ShareholderReturn ($) | Peer Group Total Shareholder Return ($) (4) | Net Income ($) | Revenue($ Millions) (5) |
| 2024 | 6,982,453 | 5,115,927 | 5,804,227 | 4,221,090 | 305.60 | 76.22 | (27.5) | 139.9 |
| 2023 | 3,081,597 | 11,796,221 | 1,808,267 | 6,263,724 | 358.40 | 72.30 | (48.6) | 89.1 |
| 2022 | 1,025,471 | 1,245,648 | 649,355 | 762,518 | 112.62 | 76.64 | (66.8) | 49.0 |
(1)
Ron Kurtz, M.D. was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.
2022-2024
Shelley Thunen
Eric Weinberg
Ilya Goldshleger, Ph.D.
(2)
The amounts shown for compensation actually paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
(3)
Compensation actually paid reflects the following exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718.
(4)
The Peer Group TSR set forth in this table utilizes the S&P Healthcare and Supplies Index (“S&P Healthcare Select Industry Index”), which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2024. The comparison assumes $100 was invested for the period starting December 31, 2021, through the end of the listed year in the Company and in the S&P Healthcare Select Industry Index, respectively, and assumes reinvestment of dividends, if any. The stock price performance shown is not necessarily indicative of future stock performance.
(5)
We determined revenue to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2024.
| Fiscal Year | 2024 |
|---|---|
| Summary Compensation Table Total for PEO ($) | 6,982,453 |
| Minus Grant Date Fair Value of Equity Awards in Summary Compensation Table ($) | (5,537,883) |
| Plus Year End Fair Value of Equity Awards Granted During Year That are Outstanding and Unvested at Fiscal Year End ($) | 2,392,712 |
| Minus Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards ($) | (1,066,451) |
| Plus Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) | 847,052 |
| Plus Change in Fair Value between the Vesting Date and the End of the Prior Year of Equity Awards Granted in Prior Years that Vested in the Year ($) | 1,498,044 |
| Minus Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year ($) | — |
| Compensation Actually Paid to PEO ($) | 5,115,927 |
| Fiscal Year | 2024 |
|---|---|
| Average Summary Compensation Table Total for Non-PEO NEOs ($) | 5,804,227 |
| Minus Non-PEO NEO Average Grant Date Fair Value of Equity Awards in Summary Compensation Table ($) | (4,919,347) |
| Plus Non-PEO NEO Average Year End Fair Value of Equity Awards Granted During Year That are Outstanding and Unvested at Fiscal Year End ($) | 2,432,900 |
| Minus Non-PEO NEO Average Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards ($) | (527,350) |
| Plus Non-PEO NEO Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) | 644,621 |
| Plus Non-PEO NEO Average Year over Year Change in Fair Value between the Vesting Date and the End of the Prior Year of Equity Awards Granted in Prior Years that Vested in the Year ($) | 786,039 |
| Minus Non-PEO NEO Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year ($) | — |
| Average Compensation Actually Paid to Non-PEO NEOs ($) | 4,221,090 |
Relationship Descriptions
Description of Relationship Between PEO and Non-PEO NEO Compensation actually paid and company Total Shareholder Return (“TSR”)
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the cumulative TSR over the three most recently completed fiscal years. The chart also compares the Company’s TSR to that of the S&P Healthcare Select Industry Index over the same period.
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our net income during the three most recently completed fiscal years.
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Revenue
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our revenue during the three most recently completed fiscal years.
Tabular List of Financial Performance Measures
The following list presents the financial performance measures that the Company considers to have been the most important in linking Compensation Actually Paid to our PEO and Non-PEO NEOs for 2024 to Company performance. The measures in this list are not ranked.
Revenue;
LAL/LAL+ Revenue;
Gross Margin; and
Cash Use.
For additional details regarding our most important financial performance measures, please see Compensation Discussion and Analysis above.
For a full reconciliation for LAL/LAL + Revenue, Gross Margin and Cash Use to the most directly comparable financial measure stated in accordance with GAAP, please see our 2024 Annual Report on Form 10-K for the fiscal year ended December 31, 2024 as filed with the SEC on February 25, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.